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Abstract
Background: Delays in the initiation of antiretroviral therapy (ART) in patients with HIV-associated tuberculosis (TB)
are associated with increased mortality risk. We examined the timing of ART among patients receiving care
provided by non-integrated TB and ART services in Cape Town, South Africa.
Methods: In an observational cohort study, we determined the overall time delay between starting treatment for
TB and starting ART in patients treated in Gugulethu township between 2002 and 2008. For patients referred from
TB clinics to the separate ART clinic, we quantified and identified risk factors associated with the two component
delays between starting TB treatment, enrolment in the ART clinic and subsequent initiation of ART.
Results: Among 893 TB patients studied (median CD4 count, 81 cells/μL), the delay between starting TB treatment
and starting ART was prolonged (median, 95 days; IQR = 49-155). Delays were shorter in more recent calendar
periods and among those with lower CD4 cell counts. However, the median delay was almost three-fold longer for
patients referred from separate TB clinics compared to patients whose TB was diagnosed in the ART clinic (116
days versus 41 days, respectively; P < 0.001). In the most recent calendar period, the proportions of patients with
CD4 cell counts < 50 cells/μL who started ART within 4 weeks of TB diagnosis were 11.1% for patients referred
from TB clinics compared to 54.6% of patients with TB diagnosed in the ART service (P < 0.001).
Conclusions: Delays in starting ART were prolonged, especially for patients referred from separate TB clinics. Non-
integration of TB and ART services is likely to be a substantial obstacle to timely initiation of ART.
Background
HIV-associated tuberculosis (TB) is associated with high
mortality risk and accounts for approximately 25% of
global HIV/AIDS deaths [1]. In addition to appropriate
antituberculosis treatment, case management requires
administration of trimethoprim-sulphamethoxazole pro-
phylaxis, which halves mortality risk [2], and antiretro-
viral therapy (ART), which reduces mortality by 64%-
95% [3]. Although ART greatly improves survival, the
optimal time to start ART during TB treatment has, for
a long time, remained unclear. However, cumulative
findings from observational studies and more recent
randomized controlled trials have demonstrated that
overall delays in ART initiation are associated with
increased mortality among TB patients across a wide
spectrum of baseline CD4 cell counts [4-7].
In response to these data, World Health Organization
(WHO) ART guidelines have been updated on several
occasions between 2002 and 2010, recommending pro-
gressively more rapid initiation of ART during TB treat-
ment [4]. The most recent revision of these guidelines
published in 2010 recommend that ART should be
given to all patients regardless of CD4 cell count and
should be started as soon as possible after TB treatment
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ment of TB treatment [8]. Data from subsequent rando-
mised controlled trials show that patients with CD4 cell
counts < 50 cells/μL have a particularly high mortality
risk and should receive ART within 2 weeks [9-11].
Despite these policy changes, the operational feasibility
of rapid initiation of ART in patients accessing routine
services in resource-limited settings is not known. In
particular the operational challenge to achieving this
within the context of separate non-integrated TB and
ART clinical services has not been assessed. In this
study we therefore quantified and explored determinants
for the delay between starting TB treatment and starting
ART among TB patients enrolling in a large township
in Cape Town, South Africa, between 2002 and 2008.
We discuss the major obstacle that non-integration of
TB and ART services is likely to represent with regard
to implementation of the 2010 WHO guidelines for the
timing of ART.
Methods
Antiretroviral treatment cohorts
The Hannan Crusaid ART clinic in Gugulethu township,
Cape Town, has provided ART free of charge since 2002.
Consistent with the South African national guidelines
[12], patients with WHO stage 4 disease (AIDS) and all
those with blood CD4 cell counts < 200 cells/μL were eli-
gible for treatment. The huge burden and complications
of TB in this ART service have been previously described
[13-16]. Here, as in most of South Africa, TB treatment
and ART have been delivered by separate primary care
clinics in different localities within the township. Thus,
patients with HIV-associated TB were referred to the
ART clinic from separate TB clinics [15]. Other patients
were referred to the ART clinic from antenatal clinics,
sexual health clinics, general medical out-patient clinics
or following discharge from an in-patient admission.
TB cases were diagnosed and notified according to
South African TB programme guidelines and TB was
treated using standardised rifampicin-based regimens of
6 months duration for new TB cases and 8 months for
retreatment cases. WHO guidelines during the period of
the study recommended that TB patients with CD4 cell
counts < 200 cells/μL should start ART within the first
2-8 weeks of TB treatment [17,18]. However, South
African ART guidelines first issued in 2004 recom-
mended that patients with CD4 cell counts < 50 cells/
μL or with serious co-morbidity start ART after 2 weeks
of TB treatment and that those with CD4 cell counts of
50-200 cells/μL start ART after 8 weeks.
Data sources
With ethical approval from the Research Ethics Com-
mittee of the University of Cape Town and written
informed consent from all patients, a prospective clinical
database has been maintained on patients enrolling in
this ART service. All patients enrolling between Septem-
ber 2002 and January 2008 were considered for inclu-
sion in this analysis. Eligible patients were ART-naive,
aged over 18 years, had a current notified diagnosis of
TB and were receiving antituberculosis therapy during
the pre-ART screening period. For each patient, demo-
graphic details, TB classification (new, retreatment, pul-
monary and extrapulmonary), WHO clinical stage,
blood CD4 cell counts and dates of TB diagnosis and
ART initiation were recorded. Where details of TB diag-
noses were missing, these were sought from patient
records, clinic TB registers and the Cape Town electro-
nic TB register. Other outcomes recorded were pre-
ART death or deferral of ART treatment due to patient
ineligibility for ART, treatment refusal or transfer to
another ART service or loss to follow-up as described
previously [19].
Statistical analyses
Patient characteristics were summarised using simple
descriptive statistics. In all analyses, patients were
grouped according to whether the patients had TB diag-
noses made in TB clinics and were then referred to the
ART clinic, or whether TB was diagnosed in the ART
clinic during the pre-ART screening period. Data col-
lected between 2002 and 2008 were aggregated into
three sequential calendar periods, 2002-2005, 2005-2006
and 2006-2008. The rationale for this was that 2005 was
the year that provider-initiated HIV testing and counsel-
ling was instituted in TB clinics and aggregation into
three periods provided adequate numbers of patients for
the statistical analyses.
The outcomes of primary interest were the time from
the start of TB treatment to start of ART and, for
patients referred from TB clinics, the two component
time periods from TB diagnosis to enrolment in the
ART clinic (a1) and from enrolment to starting ART
(a2) (Figure 1). For patients with TB diagnosed in the
ART clinic, the delay in ART was a single period
referred to as b.
Time delays to starting ART for the subset of 776
patients who did start ART were summarized using
medians and interquartile ranges and compared using
the Wilcoxon test. Time to starting ART was further
analysed using a competing risks regression model [20]
that treated pre-ART death and deferral as competing
risks to starting ART and included age, gender, calendar
period, CD4 near time of TB diagnosis, and TB classifi-
cation in addition to the group as defined by place of
diagnosis. The crude (univariate) and adjusted (multi-
variate) sub-hazard ratios (SHR) from these models are
reported along with their associated 95% confidence
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pared graphically using cumulative incidence functions.
The component periods a1 and a2 (Figure 1) were
also compared using competing risk models, adjusted
for the covariates mentioned above. The study popula-
tion was then stratified according to group, duration of
TB treatment prior to ART initiation and CD4 count
and compared using a Chi-square test.
Results
Patient characteristics and outcomes
Data were available from all 893 consecutive patients
with TB who enrolled in the service during the study
period and were included in this analysis. Of these,
675 (75.6%) had TB diagnosed in TB clinics and were
subsequently referred to the ART clinic. The remain-
ing 218 (24.4%) patients were already enrolled in the
ART clinic and had TB diagnosed during the pre-ART
screening period. The characteristics of the two groups
of patients were similar (Table 1). Patients had
advanced immunodeficiency with a median CD4 cell
count of 81 cells/μL (IQR, 35-147). TB was sputum
smear-positive pulmonary disease in 24% of cases and
30% of all cases were recurrent disease. ART was sub-
sequently started by 776 (87%) patients and, of the
remainder, 53 (6%) patients died pre-ART and treat-
ment was deferred in 64 (7%). Comparing patients
referred to the ART clinic with TB to those with TB
diagnosed in the ART clinic, the proportions who died
pre-ART (6% versus 6%) and the proportions who
were deferred (5% versus 8%) were similar.
Delays in starting ART
T h eo v e r a l ld e l a yb e t w e e nstarting TB treatment and
starting ART was 95 days (IQR, 49-155). Only 29% of
patients started ART within 8 weeks and 44% within 12
weeks (Table 2). Delays were much more prolonged for
patients referred from separate TB clinics compared to
t h o s ei nw h o mT Bw a sd i a g n o s e di nt h eA R Tc l i n i c
(Figure 2) with median delays of 116 days and 41 days,
respectively (Table 2). Of patients referred from separate
TB clinics, only 19% and 34% started ART within 8 and
12 weeks, respectively. This compares with 59% and
77%, respectively, of those with TB diagnosed within the
ART clinic (P < 0.001).
We next examined the component delays (a1 and a2;
Figure 1) associated with referral from a TB clinic. The
median delay between the start of TB treatment and
enrolment in the ART service was more than two-fold
longer than the time from enrolment to start of ART
(69 days versus 32 days, respectively; P < 0.001) (Table
2). However, once enrolled in the ART clinic, the med-
ian time to initiation of ART was similar to that of
patients whose TB was diagnosed in the ART service
(32 days versus 41 days; P = 0.326).
Risk factors associated with time to start of ART
We next explored the associations between patient char-
acteristics and the overall time to start of ART from the
start of TB treatment (Table 3). In both crude and
adjusted analyses, shorter time to ART was strongly
associated with treatment in more recent calendar peri-
ods, lower CD4 cell counts and smear-positive and
TBdiagnosed
inTBclinic
andpatient
referredfor
ART
Enrolment in
ARTclinic
Enrolment in
ARTclinic:
TBdiagnosed
duringpreͲ
ARTscreening
StartART
ɲ1 ɲ2
ɴ
Figure 1 Conceptual diagram showing the component time periods (a1, a2 and b) between tuberculosis (TB) diagnosis and starting
antiretroviral therapy (ART) for patients with TB diagnosed either in a TB clinic or in the ART clinic.
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Page 3 of 9Table 1 Characteristics of patients with tuberculosis (TB) stratified according to place of diagnosis
Patients referred from TB clinic (n = 675) Patients with TB diagnosed in ART clinic (n = 218) Total patients (n = 893)
Age, median (IQR) 33 (29-39) 33 (28-39) 33 (29-39)
Female 382 (57%) 142 (65%) 524 (59%)
CD4 cell counts,
b
Median (IQR) 81 (37-149) 83 (33-140) 81 (35-147)
0-49 191 (33%) 73 (35%) 264 (34%)
50-99 144 (25%) 46 (22%) 190 (24%)
100-149 103 (17%) 44 (22%) 147 (19%)
150-199 75 (13%) 27 (13%) 102 (13%)
≥ 200 69 (12%) 17 (8%) 86 (11%)
WHO clinical stage
3 307 (45%) 107 (49%) 414 (46%)
4 368 (55%) 111 (51%) 479 (54%)
Diagnoses made during three calendar periods
July 2002 - Aug 2005 236 (35%) 70 (32%) 306 (34%)
Sept 2005 - Aug 2006 227 (34%) 73 (34%) 300 (34%)
Sept 2006 - Jan 2008 212 (31%) 75 (34%) 287 (32%)
TB classification
a
Smear-negative pulmonary 224 (33%) 79 (36%) 303 (34%)
Smear-positive pulmonary 162 (24%) 53 (24%) 215 (24%)
Extra-pulmonary 289 (43%) 86 (40%) 375 (42%)
Retreatment TB 185 (27%) 81 (37%) 266 (30%)
a Patients with both pulmonary and extrapulmonary TB were classified as having extrapulmonary disease. Patients with no smear and not having extra-pulmonary TB were classified as smear-negative pulmonary TB
b Data available for 789 (88.4%) patients: 209 (95.0%) of patients diagnosed with TB after enrolment and 582 (86.2%) of patients diagnosed before enrolment.
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9extrapulmonary TB. In addition, the time to starting
ART was substantially longer for patients referred from
TB clinics compared to patients with TB diagnosed in
the ART clinic (Table 3). However, there was no asso-
ciation with whether the patient had a new diagnosis of
TB or they had recurrent disease.
For patients referred from TB clinics, separate analyses
were done to examine factors associated with delays in
the referral process (a1) and delays within the ART
clinic (a2). In adjusted analyses, a1 delays decreased
substantially in more recent calendar periods and were
shorter for patients with smear-positive TB but there
was no significant association with CD4 cell counts
(data not shown). In marked contrast, a2 delays were
not associated with calendar period but were substan-
tially shorter for patients with lower CD4 cell counts.
Table 2 Time delays between starting TB treatment and starting of antiretroviral therapy (ART) among patients (n =
776) who started treatment
Patients referred
from TB clinic
(n = 581)
Patients with TB
diagnosed in ART
clinic (n = 195)
All patients (n = 776)
Delay between starting TB treatment and starting ART
Median (IQR) (days) 116 (68-169) 41 (21-82) 95 (49-155)
< 2 weeks 2 (0%) 16 (8%) 18 (2%)
< 4 weeks 14 (2%) 71 (36%) 85 (11%)
< 6 weeks 62 (11%) 98 (50%) 160 (21%)
< 8 weeks 109 (19%) 115 (59%) 224 (29%)
< 12 weeks 195 (34%) 150 (77%) 345 (44%)
More than 12 weeks 386 (66%) 45 (23%) 431 (56%)
Median (IQR) time from TB diagnosis to ART clinic enrolment (a1) (days) 69 (29-115) - -
Median (IQR) time from ART clinic enrolment to ART start (a2) (days) 32 (28-51) - -
0
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Figure 2 Time to event analysis showing the cumulative proportion of patients starting antiretroviral therapy (ART) during
tuberculosis (TB) treatment. Data are stratified according to whether the patients were referred from a TB clinic or whether the TB was
diagnosed in the ART clinic.
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Page 5 of 9Delays in the most recent calendar period
Since delays in ART decreased in later calendar periods
and since those with CD4 cell counts < 50 cells/μL
derive the greatest benefit from early ART initiation, we
examined delays in the most recent period (2006-2008)
stratified by CD4 cell count (Table 4). For patients
referred from TB clinics, 36.5% of patients started ART
within 8 weeks compared to 63.2% of those with TB
diagnosed in the ART clinic (P < 0.001). The corre-
sponding proportions of patients with CD4 cell counts <
50 cells/μL who started ART within one month were
11.1% and 54.6%, respectively (P < 0.001).
Discussion
In this study, we found that time period between start-
ing TB treatment and starting ART at this clinic was
prolonged and that many patients were not treated
within the time-frames recommended under WHO and
South African guidelines that were current during the
study period. Less than half of the patients started ART
within 3 months of TB diagnosis. Most striking was the
observation that the median delay was almost three-fold
longer for patients who had to be referred for ART
from TB clinics located elsewhere in the township com-
pared to patients who had TB diagnosed in the ART
clinic. This was not explained by differences in patient
characteristics but was instead associated with lack of
integration of TB and ART services. In the most recent
calendar period, only 11.1% of patients with the highest
m o r t a l i t yr i s k( C D 4c e l lc o u n t s<5 0c e l l s / μL) were
referred from TB clinics and received ART within 4
weeks of TB diagnosis compared to 54.6% of similar
patients diagnosed in the ART clinic. For referred
patients, a majority of the overall delay occurred
between TB diagnosis and enrolment in the ART clinic
(a1). Non-integration of TB and ART services is likely
to represent a major obstacle to timely initiation of ART
in patients with HIV-associated TB and this may
obstruct progress towards reducing mortality in this
patient group.
The poor prognosis of patients with HIV-associated
TB is transformed by ART and yet mortality in
Table 3 Competing risks regression analysis of time from TB diagnosis to start of antiretroviral therapy (ART) for all
patients with CD4 cell count measurements (n = 789)
Patient characteristics Crude SHR
1 95% CI P value
1 Adjusted SHR 95% CI P value
2
Age category 0.514
18-24 1.06 0.83-1.36 0.617
25-39 1.10 0.93-1.31 0.251
≥40 1
Gender
Female 1.03 0.89-1.19 0.717
Male 1
Calendar period 0.022 0.013
Jul 2002 - Aug 2005 1 1
Sept 2005 - Aug 2006 1.20 1.03-1.41 0.019 1.26 1.05-1.51 0.013
Sept 2006 - Jan 2008 1.21 1.02-1.45 0.033 1.26 1.04-1.53 0.016
CD4 cell count < 0.001 0.001
≥200 1 1
100-199 1.65 1.29-2.11 < 0.001 1.46 1.13-1.88 0.004
50-99 1.92 1.48-2.49 < 0.001 1.83 1.40-2.38 < 0.001
0-49 1.96 1.50-2.54 < 0.001 1.71 1.30-2.26 < 0.001
TB classification
Retreatment case 1
New case 1.04 0.9-1.21 0.586
Type of TB < 0.001 < 0.001
Smear-negative PTB 1 1
EPTB 1.50 1.26-1.79 < 0.001 1.44 1.17-1.76 0.001
Smear-positive PTB 2.82 2.37-3.37 < 0.001 2.49 2.04-3.04 < 0.001
Place of TB diagnosis
TB clinic 1 1
ART clinic 1.91 1.54-2.37 < 0.001 1.88 1.51-2.34 < 0.001
1 SHR = sub-hazard ratio. Higher ratios denote more rapid initiation of ART.
2 P values in line with the heading of each variable with more than two categories were calculated using the Wald test.
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Page 6 of 9Table 4 Numbers (proportions) of patients treated in the most recent calendar period (2006-2008) that started antiretroviral therapy (ART) within the first 2,
4, 6 or 8 weeks or after more than 8 weeks of TB treatment
Duration of TB treatment prior to starting ART Patients referred from TB clinics Patients with TB diagnosed in ART clinic
All patients (n = 171) Patients with CD4 < 50 (n = 45) All patients (n = 68) Patients with CD4 < 50 (n = 22)
n (%) n (%) n (%) n (%)
< 2 weeks 1 (0.6) 1 (2.2) 6 (8.8) 3 (13.6)
< 4 weeks 6 (3.5) 5 (11.1) 25 (36.8) 12 (54.5)
< 6 weeks 31 (18.1) 20 (44.4) 36 (52.9) 18 (81.8)
< 8 weeks 62 (36.3) 31 (68.9) 43 (63.2) 20 (90.9)
< 12 weeks 98 (57.3) 38 (84.4) 54 (79.4) 21 (95.5)
More than 12 weeks 73 (42.7) 7 (15.6) 14 (20.6) 1 (4.5)
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9resource-limited settings is nevertheless very high both
before and during the initial weeks of ART [21-23]. In
light of WHO guidelines revised in 2010 and data from
randomised controlled trials, it is now clear that ART
must be started much earlier than has likely been widely
practised to date. The successful rapid scale-up of ART
in resource-limited settings has been achieved through
implementation of highly vertical ART programme.
However, an unfortunate consequence of this is that in
countries such as South Africa, TB treatment and ART
have hitherto been largely delivered in separate non-
integrated services and this is likely to be a substantial
barrier to achieving optimal care including early initia-
tion of ART. This will adversely affect those who have
the highest mortality risk who need ART most urgently.
This has been recently defined by randomised controlled
trials as treatment within 2 weeks for those with CD4
cell counts < 50 cells/μL [9,10]. The delay in starting
ART may represent an important indicator of quality of
care and that could be used for monitoring and evalua-
tion of programmes caring for patients with HIV-asso-
ciated TB.
The prolonged delays observed for patients referred
from TB clinics are likely to reflect the many steps in
the care pathway for such patients. In addition to estab-
lishing a TB diagnosis and starting TB treatment, such
patients require HIV testing, blood CD4 cell count mea-
surement, referral for ART, enrolment in the ART
clinic, reassessment for ART eligibility, preparation for
ART and finally starting ART. Each of these steps will
be associated with delays and losses that we have not
quantified in this study and these may also be com-
pounded by important factors such as stigma, fear and
lack of resources of time, energy and transportation
m o n e yt oa t t e n dc l i n i c st h a tm a yn o tb ea tt h es a m e
health facility.
As previously reported in a collaborative analysis of
data from multiple South African cohorts, the overall
time to starting ART was strongly associated with calen-
dar period and with patient CD4 cell counts [24]. How-
ever, in the present study we were able to show that the
substantial shortening of delays over sequential calendar
periods was specifically due to reductions in the referral
delay from the TB clinic. Provider initiated counselling
and HIV testing was implemented in TB clinics in this
district from 2005 onwards with high uptake and it is
likely that high coverage and timely HIV testing at TB
diagnosis was a key factor underlying this [15]. Current
mass campaigns for HIV testing may also result in a
greater proportion of patients knowing their HIV status
before presenting with HIV-related illnesses. This may
further reduce delays or, ideally, permit earlier initiation
of interventions such as isoniazid preventive therapy or
ART to prevent TB [25].
The delay within ART clinics to starting treatment
was strongly associated with CD4 cell counts, showing
an appropriate data responsiveness of health-care work-
ers. In contrast, referral delays from TB clinics were not
associated with CD4 cell counts and this is likely to
reflect lack of ready availability to CD4 count measure-
ments during the study period. This lack of data respon-
siveness may also have reflected a lack of awareness
within TB clinics of the urgency of starting ART early
in patients with low CD4 cell counts and of the need
for such referrals to be fast-tracked. This is now being
remedied locally by implementation of a fast-tracking
system using specially designed referral forms. Should
point of care CD4 cell count meters become routinely
available within the TB clinics, this may also greatly
facilitate more rapid referrals.
Strengths of this study include inclusion of a large
number of patients, precise delineation of the time
delays in ART initiation and associated risk factors, the
analysis of temporal trends and the recording of other
patient outcomes (pre-ART death and treatment defer-
ral). Weaknesses include the fact that this was a single
site study. Only TB patients who enrolled in the ART
clinic were eligible for inclusion and losses between the
time of TB diagnosis in TB clinics and enrolment in the
ART clinic have not been quantified. Any such losses,
however, would further strengthen the argument for the
need for integration of TB and ART services. Further
operational research is needed to define the component
delays along the care pathway between each of the
necessary steps (TB diagnosis, HIV testing, CD4 count
measurement, referral for ART, enrolment for ART,
initiation of ART) and how each of these can be
reduced.
Conclusion
These data show that in this district in South Africa
where care by TB and ART services was not integrated
and was delivered in different localities, potentially
adverse delays in starting ART in patients with HIV-
associated TB were largely attributable to the prolonged
time between diagnosis in the TB clinic and patient
access to the ART clinic. These data support the inte-
gration of these two services and we suggest that the
time to start ART might be used as an important indi-
cator that should be monitored as measures to improve
the care of these patients are implemented.
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